Evaluation of Safety and Efficacy of a Single Lorecivivint Injection in Patients with Knee Osteoarthritis: A Multicenter, Observational Extension Trial

Abstract Introduction Lorecivivint (LOR), a CDC-like kinase/dual-specificity tyrosine kinase (CLK/DYRK) inhibitor thought to modulate inflammatory and Wnt pathways, is being developed as a potential intra-articular knee osteoarthritis (OA) treatment. The objective of this trial was to evaluate long-...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Christopher J. Swearingen, Jeyanesh R. S. Tambiah, Ismail Simsek, Heli Ghandehari, Sarah Kennedy, Yusuf Yazici
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Adis, Springer Healthcare 2025-01-01
coleção:	Rheumatology and Therapy
Assuntos:	CLK/DYRK inhibitor Disease-modifying osteoarthritis drug (DMOAD) Knee osteoarthritis Lorecivivint Osteoarthritis Safety
Acesso em linha:	https://doi.org/10.1007/s40744-024-00731-9
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!